Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Blocking Agents | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 1091 governing therapeutic drug monitoring of anti-tumor necrosis factor (anti-TNF) blocking agents, effective May 8, 2026. Here's what billing teams need to do.

Aetna updated its coverage policy for anti-TNF drug monitoring under CPB 1091 Aetna system. This change affects practices and infusion centers that bill for therapeutic drug monitoring of biologics like adalimumab, infliximab, etanercept, and certolizumab — agents widely used in rheumatology, gastroenterology, and dermatology. The policy document does not list specific CPT or HCPCS codes, so you'll need to cross-reference your current charge capture against Aetna's updated criteria before the effective date of May 8, 2026.

Aetna Anti-TNF Therapeutic Drug Monitoring Coverage Criteria and Medical Necessity Requirements 2026

The real issue with anti-TNF therapeutic drug monitoring billing is that coverage policy for these tests sits at the intersection of lab billing, specialty pharmacy, and specialty physician billing — and each team often assumes someone else is handling it. This Aetna coverage policy update under CPB 1091 puts that gap front and center.

Therapeutic drug monitoring (TDM) for anti-TNF agents involves measuring serum drug levels and anti-drug antibody (ADA) concentrations. Clinicians use these results to guide dosing decisions — whether to escalate, switch agents, or continue current therapy. The clinical case for TDM is well-established in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), but payer coverage policy has lagged behind clinical practice. Aetna's CPB 1091 update signals the payer is tightening its criteria around when this monitoring is medically necessary and when it isn't.

Aetna's Aetna anti-TNF monitoring coverage policy under CPB 1091 has historically required that TDM be performed in the context of active disease management — not routine surveillance on stable patients. Medical necessity for anti-TNF drug level testing typically hinges on whether the patient has experienced a primary or secondary treatment failure, dose optimization is clinically indicated, or switching biologics is under consideration.

The updated policy reflects a growing body of evidence distinguishing reactive TDM (testing when symptoms return or worsen) from proactive TDM (routine testing on asymptomatic patients). Reactive TDM has a stronger evidence base for coverage. Proactive TDM remains more contested, and Aetna's coverage policy position on proactive monitoring should be reviewed carefully against the updated CPB 1091 language.

Prior authorization requirements for TDM services under Aetna vary by plan type. Commercial fully-insured plans, self-funded ASO plans, and Aetna Medicare Advantage products may carry different prior auth thresholds. Confirm which requirement applies to your patient population before the effective date of May 8, 2026.

The policy document provided does not include specific CPT or HCPCS codes. This is a meaningful gap. Anti-TNF drug monitoring typically maps to codes in the molecular diagnostic and immunology lab testing ranges, but the specific codes vary by the agent being monitored and the assay type. Your lab billing team and your outpatient specialty billing team need to be in the same room on this one.

Aetna Anti-TNF Drug Monitoring Exclusions and Non-Covered Indications

Aetna's coverage policy under CPB 1091 has consistently excluded certain TDM scenarios from reimbursement. While the specific updated exclusion language isn't available in the policy data provided here, the pattern across prior CPB 1091 versions and similar Aetna biologics policies is clear.

Proactive TDM in asymptomatic patients with no evidence of treatment failure is the highest-risk area for claim denial. Aetna has not broadly covered routine drug level monitoring for patients who are clinically stable and responding to therapy. If your gastroenterology or rheumatology practice has been billing TDM at regular intervals regardless of clinical status, this policy update is a direct trigger to review that practice.

TDM performed outside of FDA-approved or clinically validated assay platforms also carries coverage risk. Aetna looks at whether the test used is analytically validated and whether the result will change clinical management. If the documentation doesn't connect the test to a treatment decision, the claim is exposed.

Monitoring of biosimilar anti-TNF agents deserves specific attention. As biosimilar adoption grows — particularly for infliximab and adalimumab biosimilars — the TDM landscape is evolving. Coverage policy for biosimilar drug monitoring doesn't always mirror coverage for the reference biologic. Verify this with your Aetna provider relations contact or through the updated CPB 1091 document directly.

Coverage Indications at a Glance

Because the policy data does not include specific indication-level criteria or codes, the table below reflects the standard CPB 1091 framework based on known Aetna policy positions for anti-TNF TDM. Treat this as a starting framework — confirm specifics against the full CPB 1091 document at Aetna's provider portal before billing.

Confirm each row against the updated CPB 1091 text. This table is a working reference, not a substitute for the actual policy.

Aetna Anti-TNF Drug Monitoring Billing Guidelines and Action Items 2026

Here's what your team needs to do before May 8, 2026.

CPT, HCPCS, and ICD-10 Codes for Anti-TNF Therapeutic Drug Monitoring Under CPB 1091

The updated CPB 1091 policy document does not list specific CPT, HCPCS, or ICD-10 codes in the data provided for this policy change. Do not assume your current code set is correct based on prior policy versions.

Anti-TNF therapeutic drug monitoring billing spans several code categories depending on the specific assay and agent. You will need to confirm the applicable codes directly from the full CPB 1091 document. Your lab billing team should also verify whether Aetna has issued any companion lab coverage policies or fee schedule adjustments for these assays.

Until the specific codes are confirmed from the policy source, do not update charge capture or fee schedules based on inferred codes. Use the source link — app.payerpolicy.org/p/aetna/1091 — to pull the authoritative code list.